SEC Form 4 · accession 0001651844-16-000013

NYMOX PHARMACEUTICAL CORP · NYMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 21, 2016

Accepted (ET)

Mar 25, 2016 · 5:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001018735

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 21, 2016	P	1,500	$2.31	A	2,659,050	D
Common Stock	Mar 21, 2016	P	1,000	$2.34	A	2,660,050	D
Common Stock	Mar 21, 2016	P	2,000	$2.28	A	2,662,050	D
Common Stock	Mar 21, 2016	P	2,500	$2.30	A	2,664,550	D
Common Stock	Mar 21, 2016	P	2,500	$2.29	A	2,667,050	D
Common Stock	Mar 21, 2016	P	3,500	$2.29	A	2,670,550	D
Common Stock	Mar 22, 2016	P	2,500	$2.34	A	2,673,050	D
Common Stock	Mar 22, 2016	P	3,500	$2.38	A	2,676,550	D
Common Stock	Mar 22, 2016	P	3,500	$2.31	A	2,680,050	D
Common Stock	Mar 23, 2016	P	4,500	$2.34	A	2,684,550	D
Common Stock	Mar 23, 2016	P	4,500	$2.23	A	2,689,050	D
Common Stock	Mar 24, 2016	P	3,500	$2.19	A	2,692,550	D
Common Stock	Mar 24, 2016	P	5,000	$2.21	A	2,697,550	D
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust
Common Stock	holding	—	—		—	45,050	I	Trust

No Table II lines on this filing.